4.6 Article

Density Functional Studies on Secondary Amides: Role of Steric Factors in Cis/Trans Isomerization

期刊

MOLECULES
卷 23, 期 10, 页码 -

出版社

MDPI
DOI: 10.3390/molecules23102455

关键词

density functional theory; cis/trans isomerization; secondary amides; dipeptides; steric effects; tert-butyl; additivity principle

资金

  1. Department of Chemistry, UiT The Arctic University of Norway
  2. UiT The Arctic University of Norway

向作者/读者索取更多资源

Cis/trans isomerization of amide bonds is a key step in a wide range of biological and synthetic processes. Occurring through C-N amide bond rotation, it also coincides with the activation of amides in enzymatic hydrolysis. In recently described QM studies of cis/trans isomerization in secondary amides using density functional methods, we highlighted that a peptidic prototype, such as glycylglycine methyl ester, can suitably represent the isomerization and complexities arising out of a larger molecular backbone, and can serve as the primary scaffold for model structures with different substitution patterns in order to assess and compare the steric effect of the substitution patterns. Here, we describe our theoretical assessment of such steric effects using tert-butyl as a representative bulky substitution. We analyze the geometries and relative stabilities of both trans and cis isomers, and effects on the cis/trans isomerization barrier. We also use the additivity principle to calculate absolute steric effects with a gradual increase in bulk. The study establishes that bulky substitutions significantly destabilize cis isomers and also increases the isomerization barrier, thereby synergistically hindering the cis/trans isomerization of secondary amides. These results provide a basis for the rationalization of kinetic and thermodynamic properties of peptides with potential applications in synthetic and medicinal chemistry.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Multidisciplinary Sciences

Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy

Clemens Woywod, Franz X. Gruber, Richard A. Engh, Tor Fla

PLOS ONE (2017)

Article Chemistry, Multidisciplinary

Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR

Dilip Narayanan, Osman A. B. S. M. Gani, Franz X. E. Gruber, Richard A. Engh

JOURNAL OF CHEMINFORMATICS (2017)

Article Chemistry, Medicinal

Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors

Anna Czarna, Jinhua Wang, Diana Zelencova, Yao Liu, Xianming Deng, Hwan Geun Choi, Tinghu Zhang, Wenjun Zhou, Jae Won Chang, Hanne Kildalsen, Ole Morten Seternes, Nathanael S. Gray, Richard A. Engh, Ulli Rothweiler

JOURNAL OF MEDICINAL CHEMISTRY (2018)

Article Plant Sciences

Two SnRK2-Interacting Calcium Sensor Isoforms Negatively Regulate SnRK2 Activity by Different Mechanisms

Krzysztof Tarnowski, Maria Klimecka, Arkadiusz Ciesielski, Grazyna Goch, Anna Kulik, Halina Fedak, Jaroslaw Poznanski, Malgorzata Lichocka, Marcin Pierechod, Richard A. Engh, Michal Dadlez, Grazyna Dobrowolska, Maria Bucholc

PLANT PHYSIOLOGY (2020)

Correction Chemistry, Multidisciplinary

Addressing the Glycine-Rich Loop of Protein Kinases by a Multi-Facetted Interaction Network: Inhibition of PKA and a PKB Mimic (vol 56, pg 8914, 2016)

Birgit S. Lauber, Leo A. Hardegger, Alam K. Asraful, Bjarte A. Lund, Oliver Dumele, Michael Harder, Bernd Kuhn, Richard A. Engh, Francois Diederich

CHEMISTRY-A EUROPEAN JOURNAL (2020)

Article Biochemistry & Molecular Biology

Inhibitor binding to mutants of protein kinase A with GGGxxG and GxGxxA glycine-rich loop motifs

Kazi A. Alam, Osman A. S. B. M. Gani, Richard A. Engh

Summary: The conserved GxGxxG motif in protein kinases plays a crucial role in the binding of inhibitors, with different mutants showing varied binding strengths. Surprisingly, the pan-kinome inhibitor staurosporine exhibits strengthened binding in mutants due to increased binding rates.

JOURNAL OF MOLECULAR RECOGNITION (2021)

Article Biochemistry & Molecular Biology

Drugging the Undruggable: How Isoquinolines and PKA Initiated the Era of Designed Protein Kinase Inhibitor Therapeutics

Robin Lorenz, Jian Wu, Friedrich W. Herberg, Susan S. Taylor, Richard A. Engh

Summary: In 1984, Japanese researchers developed the first synthetic protein kinase inhibitors, leading to the approval of the inhibitor fasudil for medical use. These inhibitors competed against endogenous ATP, establishing the druggability of the ATP binding site. Since then, over 70 kinase inhibitors have been approved for clinical use, introducing new paradigms of data driven drug discovery.

BIOCHEMISTRY (2021)

Article Chemistry, Medicinal

Novel DYRK1A Inhibitor Rescues Learning and Memory Deficits in a Mouse Model of Down Syndrome

Wenche Stensen, Ulli Rothweiler, Richard Alan Engh, Melissa R. Stasko, Ilya Bederman, Alberto C. S. Costa, Anders Fugelli, John S. Mjoen Svendsen

Summary: Down syndrome is a complex genetic disorder with substantial physical, cognitive, and behavioral challenges. While treatment options for physical co-morbidities have improved, cognitive deficits in individuals with DS cannot be addressed pharmacologically, and all individuals with DS develop early onset Alzheimer's disease pathology by the age of 40. The study introduces a novel inhibitor for the protein kinase DYRK1A, which is a key controlling kinase associated with DS.

PHARMACEUTICALS (2021)

Article Chemistry, Physical

Cis/Trans Isomerization in Secondary Amides: Reaction Paths, Nitrogen Inversion, and Relevance to Peptidic Systems

Balmukund S. Thakkar, John-Sigurd M. Svendsen, Richard A. Engh

JOURNAL OF PHYSICAL CHEMISTRY A (2017)

Article Biochemistry & Molecular Biology

Biofocussed chemoprospecting: An efficient approach for drug discovery

Balmukund Sureshkumar Thakkar, Marte Albrigtsen, John Sigurd Svendsen, Jeanette H. Andersen, Richard Alan Engh

CHEMICAL BIOLOGY & DRUG DESIGN (2017)

暂无数据